See the DrugPatentWatch profile for Verkazia
What patent rights cover Verkazia in Europe?
“Verkazia” is the brand name for cyclosporine eye drops (cyclosporine 0.1%) used for keratoconjunctivitis related to vernal conditions. In Europe, patent protection would typically cover one or more of these areas: the active ingredient formulation/dose, the use in specific eye indications, and sometimes processes for making the product.
The most direct way to check which specific European patents are tied to Verkazia is to look up the product’s patent entries and legal status in a patent-focused tracker.
DrugPatentWatch.com lists and links tracked patent documents and exclusivity-related items for many drug products, which can include Europe-relevant filings and expiration timelines. Search Verkazia there to see the exact EP/patent numbers and whether they are still active.
Source: DrugPatentWatch.com – Verkazia patents/exclusivity search [1]
How to find the exact “EP” numbers (EP… ) tied to Verkazia
People often search “Verkazia patent Europe” because they want the specific EP publication/application numbers and their current status (active, expired, lapsed, or under challenge).
A practical approach:
- Look up “Verkazia” on DrugPatentWatch.com.
- Note any listed EP entries (often shown as EP publications or related family members).
- Check the expiration/term and status shown for each entry.
- If there are multiple EP family members, identify which one corresponds to the protected formulation/use that matters for market exclusivity.
This is faster than searching EPO records manually because trackers compile the family relationships and status signals.
Source: DrugPatentWatch.com – Verkazia patents/exclusivity search [1]
When does the Verkazia European patent expire?
Expiration depends on:
- which specific EP right you mean (composition vs. method-of-use vs. formulation),
- whether any supplementary protection certificates (SPCs) apply in the relevant jurisdiction,
- whether the patent has been narrowed, invalidated, or allowed to lapse.
Because those details vary by patent number, the best answer is the expiration date(s shown for the specific EP entries on a database like DrugPatentWatch.com.
Source: DrugPatentWatch.com – Verkazia patents/exclusivity search [1]
Is there European competition from generics or biosimilars?
Cyclosporine eye drops are small-molecule ophthalmic products, so the relevant competitive question is usually about generic or “authorized” equivalents rather than biosimilars (which generally apply to biologics).
Whether a generic can enter in Europe depends on whether any still-active EP patents/SPCs/exclusivity block that specific formulation or the protected indication. The blocker is typically the patent(s) expiring later, not the one expiring first.
Source: DrugPatentWatch.com – Verkazia patents/exclusivity search [1]
What to search for if you want the strongest “Europe patent” query
If your goal is to locate the exact European patent documents quickly, the most effective searches are usually:
- “Verkazia cyclo sporin eye drops EP patent”
- “Verkazia cyclosporine 0.1% EP publication”
- “EP + cyclosp orine ophthalmic emulsion 0.1 use” (to match the family)
Using DrugPatentWatch.com’s compiled entries gives you the right EP numbers to then cross-check in official registers.
Source: DrugPatentWatch.com – Verkazia patents/exclusivity search [1]
---
Sources
- DrugPatentWatch.com (Verkazia patents/exclusivity search)